Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Nearly one in four Latino adults in the U.S. deal with obesity, and for a long time, standard advice like “eat less and move more” just wasn’t enough for many. Enter GLP-1 drugs brand names like Ozempic, Wegovy, Mounjaro, and Zepbound. These medications were originally made to treat type 2 diabetes, but they’ve completely changed the game for weight loss.
At their core, these drugs work by mimicking the natural hormones your body uses to signal that you’re full. A lot of people taking them describe a pretty wild effect: it completely turns off “food noise” that constant, background chatter in your head telling you to eat. A 60-week study showed that people taking semaglutide felt noticeably less hungry than those on a placebo, even long after their weight loss had leveled off.
It’s no surprise that demand has blown up. Around 29 million American adults now take these drugs, driving the market to a staggering $130 billion. In fact, spending on GLP-1s surged over 500% in just five years. Within the Latino community, adults with diabetes are actually using these injectables at higher rates than almost anyone else, with over 31% currently on a prescription. That high number says a lot it shows both how urgent the medical need is and how well these drugs actually work.
Of course, they aren’t magic pills without drawbacks. The side effects are real, mostly showing up as stomach trouble like nausea, vomiting, constipation, or diarrhea, along with temporary hair loss for some. These usually kick in when you start out or bump up your dose, but they tend to settle down over time.
The bigger issue is what happens if you stop. GLP-1s are designed to be long-term treatments. When people quit taking them, the body’s natural appetite signals come roaring back, and most people regain a significant amount of weight within that first year. That weight bounce-back can be heartbreaking and mentally tough, but doctors want people to understand that it’s not a personal failure or a lack of willpower, it’s just human biology taking over once the medicine wears off.
Unfortunately, actually getting your hands on these drugs is a nightmare for most people. Even though they work, insurance coverage is a massive roadblock. Medicare, for example, strictly refuses to cover them if they’re only for weight loss. You have to have diabetes or another specific condition to get approved. There is a federal program helping lower copays for some, but that’s temporary and running out in late 2027.
To make matters worse, the system is buried in red tape. Doctors have to fill out endless paperwork, and insurance companies demand strict Body Mass Index (BMI) numbers to prove you’re “sick enough” for coverage. The problem? BMI is a pretty flawed metric that doesn’t accurately measure someone’s actual metabolic health. Since many Latino families already face barriers getting regular doctor visits, navigating all these bureaucratic hoops is an uphill battle. And even when insurance does cover a chunk, the leftover bill each month is often still way too high to afford long-term.
The bottom line is frustrating: health advocates estimate that only 2% of the people who actually need these medications can get them. That leaves millions of folks managing chronic health issues without the help modern medicine can provide. That’s why community leaders and health advocates are pushing so hard right now for real policy changes because a life-changing medical breakthrough shouldn’t just be reserved for people who can afford a massive monthly bill.
